ESR1 and breast cancer: Loi and colleagues showed that in ER-positive, HER2-negative, PIK3CA mutant breast cancers, despite apparent PI3K/AKT pathway activation, downstream mTOR1 signaling was not greatly elevated at the transcriptional and biological levels.